

05 April 2024

## The Incidence and Treatment of Colorectal Cancer

In the past 3 months, how many patients have been treated for Colorectal Cancer [CRC] with the following regimens? If possible, please also provide the split of metastatic vs non-metastatic patients for each regimen.

Regimens	Total patients	Metastatic patients	Non-Metastatic patients
Capecitabine	11		
CAPIRI	<5		
CAPOX	<5		
Cetuximab with FOLFIRI	6		
Cetuximab with FOLFOX	<5		
Cetuximab as a single agent	<5		
Cetuximab with Encorafenib	5		
Irinotecan as a single agent	<5		
FOLFIRI	17		
FOLFOX	15		
Fluorouracil (5FU) as a single agent	<5		
Oxaliplatin as a single agent	<5		
Nivolumab with Ipilimumab	<5		
Panitumumab with FOLFIRI	<5		
Panitumumab with FOLFOX	<5		
Panitumumab as a single agent	<5		
Pembrolizumab	<5		
Any other systemic anti-cancer therapy:			
- Bevacizumab & Folfiri	<5		
- Capecitabine & Oxaliplatin	38		
- Irinotecan & Capecitabine	<5		
- Irinotecan & Raltitrexed	<5		
- Lonsurf	<5		
- Mitomycin C & Capecitabine	<5		
- Nivolumab	<5		
- Oxaliplatin & Raltitrexed	<5		

- Please note metastatic information is not available.
- We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs

**05 April 2024**

are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.